Thrombocytopenia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Thrombocytopenia - Pipeline Review, H1 2016', provides an overview of the Thrombocytopenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews pipeline therapeutics for Thrombocytopenia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Thrombocytopenia therapeutics and enlists all their major and minor projects - The report assesses Thrombocytopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Thrombocytopenia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Thrombocytopenia Overview 11 Therapeutics Development 12 Pipeline Products for Thrombocytopenia - Overview 12 Pipeline Products for Thrombocytopenia - Comparative Analysis 13 Thrombocytopenia - Therapeutics under Development by Companies 14 Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 16 Thrombocytopenia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Thrombocytopenia - Products under Development by Companies 20 Thrombocytopenia - Products under Investigation by Universities/Institutes 23 Thrombocytopenia - Companies Involved in Therapeutics Development 24 3SBio Inc. 24 Amarillo Biosciences, Inc. 25 Amgen Inc. 26 Baxalta Incorporated 27 Bayer AG 28 BioLineRx, Ltd. 29 Boehringer Ingelheim GmbH 30 Bolder Biotechnology, Inc. 31 Bristol-Myers Squibb Company 32 Cellerant Therapeutics, Inc. 33 Eisai Co., Ltd. 34 Genosco 35 Hansa Medical AB 36 Immunomedics, Inc. 37 Intas Pharmaceuticals Ltd. 38 Jiangsu Hengrui Medicine Co., Ltd. 39 Merck & Co., Inc. 40 Momenta Pharmaceuticals, Inc. 41 Myelo Therapeutics GmbH 42 Neumedicines Inc. 43 Novartis AG 44 Pfizer Inc. 45 PhytoHealth Corporation 46 Prophylix Pharma AS 47 Protalex, Inc. 48 Rigel Pharmaceuticals, Inc. 49 Shionogi & Co., Ltd. 50 STATegics, Inc. 51 UCB S.A. 52 ViroMed Co., Ltd. 53 Thrombocytopenia - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 58 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 avatrombopag - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 BBT-059 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 BI-655064 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 BL-8040 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 BMS-986004 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 CLT-009 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 eltrombopag olamine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 eltrombopag olamine - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 fostamatinib disodium - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 GL-2045 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 GSK-2285921 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Hetrombopag Olamine - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 interferon alfa - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 lusutrombopag - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 MK-8723 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Myelo-001 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 NMIL-121 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 PBF-1509 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 PEG-VM501 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 PHN-013 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 PRTX-100 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 rivaroxaban - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 romiplostim - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 romiplostim biosimilar - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 SKIO-703 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 SM-101 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 STST-4 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 thrombopoietin - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 Tromplate - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 TXA-302 - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 UCB-7665 - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 veltuzumab - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 Thrombocytopenia - Recent Pipeline Updates 129 Thrombocytopenia - Dormant Projects 165 Thrombocytopenia - Discontinued Products 168 Thrombocytopenia - Product Development Milestones 169 Featured News & Press Releases 169 Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia 169 Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP 170 Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 171 Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 172 Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 172 Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 173 Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia 174 Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia 174 Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 175 Sep 04, 2015: Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 175 Appendix 177 Methodology 177 Coverage 177 Secondary Research 177 Primary Research 177 Expert Panel Validation 177 Contact Us 177 Disclaimer 178
List of Tables
Number of Products under Development for Thrombocytopenia, H1 2016 12 Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Thrombocytopenia - Pipeline by 3SBio Inc., H1 2016 24 Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H1 2016 25 Thrombocytopenia - Pipeline by Amgen Inc., H1 2016 26 Thrombocytopenia - Pipeline by Baxalta Incorporated, H1 2016 27 Thrombocytopenia - Pipeline by Bayer AG, H1 2016 28 Thrombocytopenia - Pipeline by BioLineRx, Ltd., H1 2016 29 Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 30 Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H1 2016 31 Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H1 2016 32 Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016 33 Thrombocytopenia - Pipeline by Eisai Co., Ltd., H1 2016 34 Thrombocytopenia - Pipeline by Genosco, H1 2016 35 Thrombocytopenia - Pipeline by Hansa Medical AB, H1 2016 36 Thrombocytopenia - Pipeline by Immunomedics, Inc., H1 2016 37 Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 38 Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 39 Thrombocytopenia - Pipeline by Merck & Co., Inc., H1 2016 40 Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 41 Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H1 2016 42 Thrombocytopenia - Pipeline by Neumedicines Inc., H1 2016 43 Thrombocytopenia - Pipeline by Novartis AG, H1 2016 44 Thrombocytopenia - Pipeline by Pfizer Inc., H1 2016 45 Thrombocytopenia - Pipeline by PhytoHealth Corporation, H1 2016 46 Thrombocytopenia - Pipeline by Prophylix Pharma AS, H1 2016 47 Thrombocytopenia - Pipeline by Protalex, Inc., H1 2016 48 Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 49 Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H1 2016 50 Thrombocytopenia - Pipeline by STATegics, Inc., H1 2016 51 Thrombocytopenia - Pipeline by UCB S.A., H1 2016 52 Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H1 2016 53 Assessment by Monotherapy Products, H1 2016 54 Number of Products by Stage and Target, H1 2016 56 Number of Products by Stage and Mechanism of Action, H1 2016 59 Number of Products by Stage and Route of Administration, H1 2016 62 Number of Products by Stage and Molecule Type, H1 2016 64 Thrombocytopenia Therapeutics - Recent Pipeline Updates, H1 2016 129 Thrombocytopenia - Dormant Projects, H1 2016 165 Thrombocytopenia - Dormant Projects (Contd..1), H1 2016 166 Thrombocytopenia - Dormant Projects (Contd..2), H1 2016 167 Thrombocytopenia - Discontinued Products, H1 2016 168
List of Figures
Number of Products under Development for Thrombocytopenia, H1 2016 12 Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Assessment by Monotherapy Products, H1 2016 54 Number of Products by Top 10 Targets, H1 2016 55 Number of Products by Stage and Top 10 Targets, H1 2016 55 Number of Products by Top 10 Mechanism of Actions, H1 2016 58 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 58 Number of Products by Routes of Administration, H1 2016 61 Number of Products by Stage and Routes of Administration, H1 2016 61 Number of Products by Top 10 Molecule Types, H1 2016 63 Number of Products by Stage and Top 10 Molecule Types, H1 2016 63
North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption ratRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.